The purpose of the observational study is to evaluate the safety and effectiveness of combination therapy with nivolumab and ipilimumab in Japanese participants with advanced or metastatic renal cell carcinoma (aRCC) in the real-world setting in Japan.
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms J-ENCORE
- Sponsors Bristol-Myers K.K.
Most Recent Events
- 14 Feb 2025 Status changed from active, no longer recruiting to completed.
- 25 May 2022 Planned End Date changed from 1 Aug 2022 to 23 Aug 2024.
- 25 May 2022 Planned primary completion date changed from 1 Aug 2022 to 23 Aug 2024.